
Our Mission: Optimizing the standard of wound care through innovations grounded in science, compassion, and collaboration.
Our Vision: Raising the standard of caring.

Origin Story
"Before co-founding BioLab Holdings I had a long and successful career in the telecommunications industry. At the age of 50, I decided to return to school to get my executive MBA to sharpen my skills and fill any knowledge gaps I had. It proved very impactful, as it allowed me to see other people at different stages in their careers, and what some of them were achieving or not achieving. It made me reflect internally on what I was doing and how I was using my skills.
On my last day of grad school, I had a life-altering moment — a rollover car accident from which I miraculously walked away without a scratch. The next day I was on a plane to Rochester, New York to start a new position and couldn’t help but wonder, “Am I really doing anything to help improve lives or to help others?”. And the answer — painfully — was no. I was helping businesses become more efficient, but I really wasn’t changing lives.
I wanted to create value for other human beings. So, I made a career shift from software sales to regenerative medicine. Yes, it was a big transition, but we are so fortunate today to have a wealth of information at our fingertips. You truly can learn to do anything new you want.
It’s been a great journey to where I am now. Regenerative medicine has come a long way in five years, and I think it’s going to keep progressing tremendously as we learn more about how the body can help heal itself. This path is enabling me to help people who are suffering from hard-to-heal wounds. We’re helping save people’s limbs. We’re absolutely changing lives and improving the quality of it for countless individuals. For me, this line of work definitely feels much better than saving a company money or helping a company achieve a better business plan."
-Bob Maguire, Chairman of the Board
Leadership Team
Robert (Bob) Maguire founded BioLab Holdings in April 2018 and serves as Chairman of the Board & Founder, bringing over 40 years of leadership experience to BioLab. After a life-changing event, he founded the company with a mission to improve lives through regenerative medicine. Mr. Maguire’s extensive background in biotech innovation and collaboration with top institutions has shaped BioLab’s purpose-driven approach. In 2023 and 2025, Mr. Maguire and co-founder Jaime Leija was recognized by Arizona State University as part of the ASU 100, achieving the #1 rank in 2023.
Mr. Maguire holds a B.A. from Manhattan University and an Executive MBA from Arizona State University - W.P. Carey School of Business.
Jaime Leija co-founded BioLab Holdings in April 2018 and serves as President & CEO, bringing over 20 years of experience in sales leadership, marketing, and operations. Prior to BioLab Holdings, Mr. Leija held the position of Region Vice President of Sales for IKON Office Solutions, AOT-Xerox, and Advance Laboratory Consultants. Beyond his professional commitments, Mr. Leija is passionate about youth sports and their role in shaping the lives of young people. Together with his wife and family, Mr. Leija runs a non-profit organization, The Competitive Youth Sports Foundation of Arizona, which helps low to moderate-income families have access to sports teams, camps, and equipment. Mr. Leija is also actively involved with his alma mater, Arizona State University where he serves as a member of the Sales Advisory Council for the Professional Sales Program and mentors college students aspiring for careers in Professional Sales and Marketing. In 2025, Mr. Leija and founder Robert Maguire was recognized by AZ Big Media as part of the AZ Big 100: 50 Arizona Business Leaders to Watch in 2025. Additionally, both were honored with the 2025 Ernst and Young (EY) Entrepreneurs of the Year Award for the Pacific Southwest.
Scott Swonger joined BioLab Holdings in July 2019 as Chief Financial Officer, bringing over 40 years of experience as a financial management leader for health, technology and environmental companies. Prior to BioLab Holdings, Mr. Swonger held executive-level finance positions in highly regulated, hyper-growth industries. Mr. Swonger has successfully completed dozens of mergers, acquisitions, and divestitures in a variety of these service and manufacturing entities.
Mr. Swonger holds a B.S. in Business Administration and International Finance from Miami University.
Dr. Carlos Encinas joined BioLab Holdings in January 2020 as Chief Science Officer, bringing 20 years of experience in technology transfer, identifying, protecting and commercializing inventions developed at academic institutions. Prior to BioLab, Dr. Encinas managed early-stage technology-based companies and represented these academic institutions at an international level, primarily in Europe and South America.
Dr. Encinas holds a Bachelor’s Degree in Biotechnology Engineering from the Technology Institute of Sonora, an MBA in Business Administration and a Ph.D. in Molecular Biology at the University of Arizona.
Marshall Medley, DO, FACOS, CWS-P, Chief Medical Officer for BioLab Holdings is board certified in vascular surgery and has dealt with acute and chronic wounds for 20 years. His surgical experience has exposed him to many different wounds and wound pathologies. He has served as a medical director for two different wound care and hyperbaric oxygen centers over his career.
His role at BioLab Holdings is to assist with development of new products, generate protocols and indications for products, and train clinicians and the sales force in the use and application of these products. His goal is to get the products in the hands of the clinicians to help them help the patients heal. Having practiced in wound care for many years, it is his goal to help others be successful and help these patients get on with their lives.
Prior to his work at BioLab Holdings, he was in private and employed practice in vascular surgery and wound care in several hospitals in southeast Michigan. He now resides in Utah and travels to meet clinicians and others about these products. His bachelors degree in Biology is from California State University at San Bernardino, a Doctor of Osteopathic Medicine degree from Western University of Health Sciences in Pomona, CA, General Surgery Residency through Michigan State University, and a vascular surgery fellowship in Dayton, OH through Ohio University and Grandview Hospital and Medical Center.
Marty Kuser joined BioLab Holdings in January 2023 and serves as Chief Commercialization Officer, bringing over 25 years of experience in the medical device sector, with an additional 15 years in sales leadership, and 10 years dedicated to human tissue and regenerative medicine. Prior to BioLab, Mr. Kuser was the Vice President of Sales at Aziyo Biologics, and has held leadership positions at Xtant Medical, Bone Bank Allografts, and multiple medical device companies.
Mr. Kuser holds a BBA in Marketing from Loyola University of Maryland.